The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation

This study has been completed.
Sponsor:
Information provided by:
INO Therapeutics
ClinicalTrials.gov Identifier:
NCT00060840
First received: May 14, 2003
Last updated: September 17, 2010
Last verified: September 2010
  Purpose

The purpose of this study is to assess the utility of nitric oxide for inhalation during left ventricular assist device (LVAD) implantation following cardiopulmonary bypass (CPB). This is to be assessed by the number of patients in each treatment group meeting failure criteria within 24 hours on study drug, as defined by two or more of the following:

  • Left ventricular flow rate index (LVFRI) ≤ 2.0 L/min/m^2
  • Administration of ≥ 20 inotropic equivalents (IE)

    • 10 µg/kg/min dopamine, dobutamine, enoximone or amrinone is equivalent to 10 IE
    • 0.1 µg/kg/min epinephrine or norepinephrine is equivalent to 10 IE
    • 1 µg/kg/min milrinone is equivalent to 15 IE
    • 0.1 U/min vasopressin is equivalent to 10 IE
  • Mean arterial pressure (MAP) ≤ 55 mmHg
  • Central venous pressure (CVP) ≥ 16 mmHg
  • Percent mixed venous oxygen saturation (SvO2) ≤ 55%

Or at least one of the following criteria:

  • Failure to wean from cardiopulmonary bypass at least once due to hemodynamic failure. Re-initiation of cardiopulmonary bypass to correct bleeding or other technical issues will not be considere 'failure to wean'
  • Death

Condition Intervention Phase
Congestive Heart Failure
Drug: Nitric Oxide
Drug: Nitrogen
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Nitric Oxide for Inhalation During Left Ventricular Assist Device (LVAD) Implantation

Resource links provided by NLM:


Further study details as provided by INO Therapeutics:

Primary Outcome Measures:
  • The Number of Subjects With Left Ventricular Failure During Left Ventricular Assistance Device (LVAD) Placement After Cardio Pulmonary Bypass, as Determined by Failure Criteria, After Administration of Nitric Oxide. [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]

    Failure criteria used to measure outcome includes:

    • Left ventricular flow rate index (LVFRI) ≤ 2.0 L/min/m^2
    • Administration of ≥ 20 inotropic equivalents (IE)
    • Mean arterial pressure (MAP) ≤ 55 mm Hg
    • Central venous pressure (CVP) ≥ 16 mm Hg
    • Percentage of mixed venous oxygen saturation (SvO2) of ≤ 55% OR failure to wean from cardio pulmonary bypass (CPB) at least once due to hemodynamic failure or death.


Enrollment: 150
Study Start Date: July 2003
Study Completion Date: July 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Inhaled Nitric Oxide
Inhaled Nitric Oxide (iNO) at 40 parts per million (ppm)
Drug: Nitric Oxide
40 ppm of Nitric Oxide continuously administered for 48 hours
Other Name: INOmax
Placebo Comparator: Nitrogen
Nitrogen (N2) administered at 40 ppm.
Drug: Nitrogen
Nitrogen (N2) administered at 40 ppm for 48 hours
Other Name: Nitrogen

Detailed Description:

40 ppm of either nitric oxide for inhalation or N2 (placebo) will be continuously administered to the patient starting at least 5 minutes prior to initiating the first weaning attempt from CPB and continue until the patient is either extubated, has reached failure criteria, or has been treated with study drug for 48 hours following discontinuation of CPB, whichever come first.

All patients will be monitored peri-operatively with a pulmonary arterial line, central venous line, and systemic arterial line. Baseline data collection by a designated clinical staff member will begin following induction of anesthesia and prior to skin incision. Following a successful wean from cardiopulmonary bypass, post-op data will be collected within 1 hour following end time of surgery. Data will then be collected at 6, 12, 18, 24, and 48 hours from post-op or until extubation, in which case weaning from study drug will begin.

Open label investigational nitric oxide for inhalation may be administered once a patient meets a minimum of two of the failure criteria or fails to wean at least once due to hemodynamic failure from cardiopulmonary bypass.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Scheduled to undergo their first LVAD implantation, (or at least 6 months after explanation of a previous LVAD).
  • Has a pulmonary vascular resistance of at least 2.5 Wood units (200 dynes/sec.) in the 30 days prior to LVAD placement.
  • Greater than 18 years of age.
  • Signed IRB approved informed consent.

Exclusion criteria:

  • Patients with congestive heart failure due to giant cell myocarditis or restrictive cardiomyopathy.
  • Elective Biventricular Assist Device (BiVAD) surgery, or current support with a temporary BiVad.
  • LVAD procedure expected to be done without cardiopulmonary bypass.
  • Pregnancy (a negative pregnancy test must be documented prior to enrollment).
  • Received nitric oxide by inhalation therapy within the past 24 hours.
  • Investigational drugs that are expected to change systemic or pulmonary vascular resistance are not allowed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00060840

Locations
United States, New Jersey
Newark Beth Isreal Medical Center
Newark, New Jersey, United States, 07112
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45219
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Texas
University of Texas/St. Paul Medical Center
Dallas, Texas, United States, 75390
Baylor University Medical Center
Dallas, Texas, United States, 75226
Texas Heart Institute
Houston, Texas, United States, 20345
Germany
Herz-und Diabeteszentrum Nordrhein-Westfalen
Gergstrab, Bad Oeynhausen, Germany, 32545
Deutsches Herfzzentrum Berlin
Augustenburger Platz, Berlin, Germany, 13353
United Kingdom
Harefield Hospital
Harefield, Middlesex, United Kingdom, UB96JH
Sponsors and Collaborators
INO Therapeutics
Investigators
Study Director: James Baldassarre, MD INO Therapeutics
  More Information

No publications provided

Responsible Party: Rob Small, INO Therapeutics
ClinicalTrials.gov Identifier: NCT00060840     History of Changes
Other Study ID Numbers: INOT 41
Study First Received: May 14, 2003
Results First Received: August 25, 2010
Last Updated: September 17, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by INO Therapeutics:
Left Ventricular Assist Device Implantation
Progressive Left Ventricular Failure

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Nitric Oxide
Anti-Asthmatic Agents
Antioxidants
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Endothelium-Dependent Relaxing Factors
Free Radical Scavengers
Gasotransmitters
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on October 23, 2014